$0.20
(Market cap
$58 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
11.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-12.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.5
-
Face value
--
-
Shares outstanding
5,103,002
5 Years Aggregate
CFO
$-70.74 Mln
EBITDA
$-117.55 Mln
Net Profit
$-111.94 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mink Therapeutics Inc (INKT)
| 3.4 | 9.8 | -3.6 | -16.8 | -7.6 | -- | -- |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Mink Therapeutics Inc (INKT)
| 60.0 | -34.6 | -59.0 | -41.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mink Therapeutics Inc (INKT)
|
11.5 | 58.3 | 0.0 | -11.4 | -- | -- | -- | 11.3 |
| 84.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 73.3 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 545.9 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 595.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.9 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Mink Therapeutics Inc (INKT)
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and... other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. Read more
-
Executive Chairman
Dr. Garo H. Armen Ph.D.
-
Executive Chairman
Dr. Garo H. Armen Ph.D.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Mink Therapeutics Inc (INKT)
What is the current share price of Mink Therapeutics Inc (INKT) Today?
The share price of Mink Therapeutics Inc (INKT) is $11.53 (NASDAQ) as of 03-Sep-2026 09:48 EDT. Mink Therapeutics Inc (INKT) has given a return of -7.57% in the last 3 years.
What is the current PB & PE ratio of Mink Therapeutics Inc (INKT)?
Since, TTM earnings of Mink Therapeutics Inc (INKT) is negative, P/E ratio is not available.
The P/B ratio of Mink Therapeutics Inc (INKT) is 11.33 times as on 28-Aug-2026, a 119 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.81 |
-3.35 |
2024 |
-0.24 |
-0.13 |
2023 |
-0.16 |
-0.20 |
2022 |
-0.32 |
-21.99 |
2021 |
-0.49 |
0.62 |
What is the 52 Week High and Low of Mink Therapeutics Inc (INKT)?
The 52-week high and low of Mink Therapeutics Inc (INKT) are Rs 16.93 and Rs 8.48 as of 03-Sep-2026.
What is the market cap of Mink Therapeutics Inc (INKT)?
Mink Therapeutics Inc (INKT) has a market capitalisation of $ 58 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Mink Therapeutics Inc (INKT)?
Before investing in Mink Therapeutics Inc (INKT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.